<DOC>
	<DOCNO>NCT00973128</DOCNO>
	<brief_summary>The present study design randomize , single blind , placebo-controlled , study evaluate effect 400 Âµg recombinant human GM-CSF apply intralesionally associate half total dose antimony reduce time schedule ( 20mgSbV/Kg/d 10 day ) compare full dose antimony ( 20mgSbV/Kg/d 20 day ) treat cutaneous leishmaniasis ulcer .</brief_summary>
	<brief_title>Reduced Doses Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor ( GM-CSF ) Cutaneous Leishmaniasis</brief_title>
	<detailed_description>This randomize , single blind placebo-controlled study group select case present health post . The inclusion criterion : age 15 50 year , either sex , diagnosis cutaneous leishmaniasis le 60 day . The diagnostic criterion presence typical single cutaneous ulcer , localize low limb , positive delay type hypersensitivity test ( DTH Montenegro skin test ) Leishmania antigen .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<criteria>Age 15 50 year Either gender Diagnosis cutaneous leishmaniasis Less 60 day disease Any history prior antileishmania therapy Negative parasitology ( aspirate/smear ) negative Montenegro test Pregnancy Age 15 50 year Other associate acute chronic illness History allergy GMCSF and/or antimony HIV , HTLV1 infection diabetes Administrative reason : Lack ability willingness give inform consent ( patient and/or parent / legal representative ) Anticipated nonavailability study visits/procedures</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>